Background: The apolipoprotein E (APOE) e4 genetic polymorphism is a major risk factor for Alzheimer' s disease, hence the possible prevention of its detrimental effects on cognition is of high relevance. Methods: We used linear regression models to assess associations of APOE e4 with cognitive performance in a population-based cohort study (n = 1,434) and in a cohort of patients with coronary heart disease (n = 366), and restricted cubic splines to explore dose-response relationships between serum cholesterol levels and cognition depending on APOE polymorphism. Results: The association of APOE e4 with cognitive function was strongly amplified in the presence of hypercholesterolemia and cardiovascular disease in both independent cohorts; hypercholesterolemia was associated with cognitive function only among APOE e4 carriers in the presence of cardiovascular disease. The interaction effect between APOE genotype and hypercholesterolemia was statistically significant in both cohorts. Conclusions: The detrimental effects of APOE e4 polymorphism on cognition may strongly depend on modifiable risk factors.

Keywords:
Prevention, Risk factors, Alzheimer’s disease, Cognitive decline, Hypercholesterolemia
1.
Liu CC, Kanekiyo T, Xu H, Bu G: Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy. Nat Rev Neurol 2013;9:106-118.
2.
Mahley RW: Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-630.
3.
Villeneuve S, Brisson D, Marchant NL, Gaudet D: The potential applications of apolipoprotein E in personalized medicine. Front Aging Neurosci 2014;6:154.
4.
Brainerd CJ, Reyna VF, Petersen RC, Smith GE, Kenney AE, Gross CJ, Taub ES, Plassman BL, Fisher GG: The apolipoprotein E genotype predicts longitudinal transitions to mild cognitive impairment but not to Alzheimer's dementia: findings from a nationally representative study. Neuropsychology 2013;27:86-94.
5.
Heun R, Gühne U, Luck T, Angermeyer MC, Ueberham U, Potluri R, Natalwala A, Arendt T, Riedel-Heller SG: Apolipoprotein E allele 4 is not a sufficient or a necessary predictor of the development of mild cognitive impairment. Eur Psychiatry 2010;25:15-18.
6.
Small BJ, Rosnick CB, Fratiglioni L, Backman L: Apolipoprotein E and cognitive performance: a meta-analysis. Psychol Aging 2004;19:592-600.
7.
Wood WG, Li L, Müller WE, Eckert GP: Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis. J Neurochem 2014;129:559-572.
8.
Anstey KJ, Lipnicki DM, Low LF: Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry 2008;16:343-354.
9.
Rohn TT: Is apolipoprotein E4 an important risk factor for vascular dementia? Int J Clin Exp Pathol 2014;7:3504-3511.
10.
Qiu C, Fratiglioni L: A major role for cardiovascular burden in age-related cognitive decline. Nat Rev Cardiol 2015;12:267-277.
11.
Perna L, Schöttker B, Holleczek B, Brenner H: Serum 25-hydroxyvitamin D and incidence of fatal and nonfatal cardiovascular events: a prospective study with repeated measurements. J Clin Endocrinol Metab 2013;98:4908-4915.
12.
Mons U, Hahmann H, Brenner H: A reverse J-shaped association of leisure time physical activity with prognosis in patients with stable coronary heart disease: evidence from a large cohort with repeated measurements. Heart 2014;100:1043-1049.
13.
Kliegel M, Martin M, Jäger T: Development and validation of the Cognitive Telephone Screening Instrument (COGTEL) for the assessment of cognitive function across adulthood. J Psychol 2007;141:147-170.
14.
Breitling LP, Wolf M, Müller H, Raum E, Kliegel M, Brenner H: Large-scale application of a telephone based test of cognitive functioning in older adults. Dement Geriatr Cogn Disord 2010;30:309-316.
15.
Zivelin A, Rosenberg N, Peretz H, Amit Y, Kornbrot N, Seligsohn U: Improved method for genotyping apolipoprotein E polymorphism by a PCR-based assay simultaneously utilizing two distinct restriction enzymes. Clin Chem 1997;43:1657-1659.
16.
Vossen CY, Hoffmann MM, Hahmann H, Wüsten B, Rothenbacher D, Brenner H: Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program. Clin Pharmacol Ther 2008;84:222-227.
17.
Perna L, Wahl HW, Mons U, Saum KU, Holleczek B, Brenner H: Cognitive impairment, all-cause and cause-specific mortality among non-demented older adults. Age Ageing 2015;44:445-451.
18.
Burger M, Ziese T: Bundes-Gesundheitssurvey: Alkohol - Konsumverhalten in Deutschland. Berlin, Robert Koch-Institut, 2003. https://www.gbe-bund.de/pdf/alkohol.pdf.
19.
Desquilbet L, Mariotti F: Dose-response analyses using restricted cubic spine functions in public health research. Stat Med 2010;29:1037-1057.
20.
Knight RG, Tsui HS, Abraham WC, Skeaff CM, McMahon JA, Cutfield NJ: Lack of effect of the apolipoprotein E e4 genotype on cognition during healthy aging. J Clin Exp Neuropsychol 2014;15:1-9.
21.
Brainerd CJ, Reyna VF, Petersen RC, Smith GE, Taub ES: Is the apolipoprotein e genotype a biomarker for mild cognitive impairment? Findings from a nationally representative study. Neuropsychology 2011;25:679-689.
22.
de Bruijn RF, Akoudad S, Cremers LG, Hofman A, Niessen WJ, van der Lugt A, Koudstaal PJ, Vernooij MW, Ikram MA: Determinants, MRI correlates, and prognosis of mild cognitive impairment: the Rotterdam Study. J Alzheimers Dis 2014;42(suppl 3):S239-S249.
23.
Reinvang I, Espeseth T, Westlye LT: APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease. Neurosci Biobehav Rev 2013;37:1322-1335.
24.
Kalmijn S, Feskens EJM, Launer LJ, Kromhout D: Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men. Stroke 1996;27:2230-2235.
25.
Reed B, Villeneuve S, Mack W, DeCarli C, Chui HC, Jagust W: Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol 2014;71:195-200.
26.
Yasuno F, Tanimukai S, Sasaki M, Hidaka S, Ikejima C, Yamashita F, Kodama C, Mizukami K, Michikawa M, Asada T: Association between cognitive function and plasma lipids of the elderly after controlling for apolipoprotein genotype. Am J Geriatr Psychiatry 2012;20:574-583.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.